Elanco’s Season of Purpose is underway! We kicked off in Kiel, Germany, where team members gave back in big ways — from charity runs supporting local animal welfare organizations to beach cleanups that help wildlife thrive. 🏃♀️🐾 Together, our 9,000 employees are on a mission to contribute 25,000 volunteer hours around the world. We can’t wait to see how Elanco teams across the globe step up during this Season of Purpose and on Global Day of Purpose 2025. 💙 #WeAreElanco #GDOP2025
On National Food Bank Day, we’re reminded that food insecurity is a global challenge and one we’re addressing in the communities where we live and work. In 2024, our employees: - Volunteered 730 hours at food pantries - Packed more than 115,000 meals to feed families in need worldwide We’re committed to protecting access to affordable, high-quality protein for our local communities and are proud of our employees that go beyond to nourish society. #WeAreElanco #GoBeyond
Today, we celebrate the incredible contributions of our interns who bring fresh perspectives, innovative ideas, and boundless energy to Elanco. As vital members of our team, they help drive meaningful projects and challenge us to think differently. Their dedication and enthusiasm are paving the way for the next generation in the workforce, and we're grateful for their impact on our organization's growth and success. Thank you to all our interns for your hard work and creativity! Here's to continued learning and collaboration as we #GoBeyond together! #WeAreElanco #NationalInternDay
We are proud to share that Elanco was one of the companies recognized in U.S. News & World Report’s 2025 list of the best places to work! Nearly 500 companies were evaluated across six key areas: - Quality of pay and benefits - Work-life balance - Job stability - Belonging and self-esteem - Professional development - Physical and psychological comfort Elanco was one of just three Indiana-based employers to make the list!
At Elanco, our commitment to animal health goes beyond developing innovative products and extends to supporting the organisations that make a difference in animals' lives. It is our privilege to support the incredible work being done at the Small Animal Specialist Hospital (SASH) through its blood donor program. With over 200 veterinarians and 500 nurses working across their hospitals, SASH offers a unique opportunity to engage with a wide network of veterinary professionals dedicated to saving lives and advancing animal health.
Recently, Elanco marked a significant milestone at its Huningue, France site by breaking ground on a 5,000 sq/m site expansion project. The site specializes in tablet production, so this expansion will help meet increased product demand and support the production of Elanco's latest innovations, helping pets live longer healthier lives. Elanco is one of only two Animal Health companies that manufactures products in all four Pet Health categories—parasiticides, dermatology, pain, and vaccines. The Huningue, France site manufactures three of these four categories. Over the past several years, the site has been expanding to further enable Elanco's ability to support product innovation for its pet health customers around the world.
Exciting news! Elanco is expanding its pet health portfolio with Pet Protect™ from the Makers of Advantage®, a veterinarian-formulated, science-backed supplement line designed to support pets’ overall wellness. From joint health and digestion to calming support and skin health, Pet Protect offers comprehensive solutions for proactive pet care.
It’s an exciting day as we strengthen our dairy portfolio and advance animal health solutions that support dairy and poultry farmers while helping stabilize egg prices. We’ve partnered with South Dakota-based Medgene to commercialize a highly pathogenic avian influenza (HPAI) vaccine for dairy cattle. The vaccine has met USDA platform technology requirements and is in final review for conditional approval. Medgene has ready-to-supply vaccines to support the U.S. dairy industry upon approval. This vaccine can slow virus spread, protect dairy and poultry producers, and help stabilize egg prices.
We’re celebrating six consecutive quarters of organic constant currency revenue growth and continued acceleration across our global portfolio. With six potential blockbuster products launched, we're on track to generate $640–720M in innovation revenue in 2025. Our Q4 and full-year 2024 results showcase the strength of our diversified business and innovation-driven strategy.
Scratching, rubbing, chewing, licking. All signs of an irritated, itchy dog. Today, Elanco Animal Health Incorporated (NYSE: ELAN), is introducing some of the first allergic dogs who have found zen and gotten back to normal by using Zenrelia. Zenrelia, which was approved by the U.S. Food and Drug Administration (FDA) and launched in September 2024, is a highly effective, convenient and safe once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
